Shireen V Guide, MD
Dermatology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 3 carriers
- Offices
- 2
Offices
2 locations · Lpch Medical Group Div of Lucile · 332 clinicians in this group
Plans that list them
14 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Guide’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A95744 · Current
Licensed to practise in California · since 2006 · expires 2028-02-29 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$204,018
Medicare paid this office $204,018 for 304 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 211 | $35,311 | $71 |
| Return visit (30+ min) | 168 | $30,845 | $105 |
| Destruction of skin growth, 1-14 growths | 149 | $18,331 | $91 |
| Biopsy of related skin growth, first growth | 153 | $14,695 | $71 |
| Destruction of precancer skin growth, 1 growth | 169 | $12,105 | $40 |
See all 21 services
| Short return visit (20+ min) | 211 | $35,311 | $71 |
| Return visit (30+ min) | 168 | $30,845 | $105 |
| Destruction of skin growth, 1-14 growths | 149 | $18,331 | $91 |
| Biopsy of related skin growth, first growth | 153 | $14,695 | $71 |
| Destruction of precancer skin growth, 1 growth | 169 | $12,105 | $40 |
| Biopsy of related skin growth, each additional growth | 108 | $10,542 | $45 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 17 | $10,203 | $486 |
| Punch biopsy, first skin growth | 64 | $7,838 | $106 |
| Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | 16 | $5,543 | $346 |
| Destruction of precancer skin growth, 2-14 growths | 130 | $5,133 | $6 |
| New patient visit (30+ min) | 50 | $4,253 | $85 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 14 | $3,222 | $129 |
| New patient visit (45+ min) | 20 | $2,287 | $114 |
| Punch biopsy, each additional skin growth | 18 | $1,327 | $53 |
| Administration of chemotherapy into growth, 1-7 | 19 | $1,274 | $51 |
| Removal of noncancer skin growth of body, arms, or legs, 1.1-2.0 cm | 12 | $995 | $77 |
| Short return visit | 21 | $970 | $44 |
| Biopsy of ear | 12 | $592 | $49 |
| Injection into skin growth, 1-7 growths | 12 | $438 | $29 |
| Injection, fluorouracil, 500 mg | 20 | $63 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $11 | None |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 35 | More than 82% of doctors who do this |
| Removal of skin cancer | 58 | More than 17% of doctors who do this |
| Removal of skin lesions | 1131 | More than 94% of doctors who do this |
| Removal or shaving of skin growth | 1-10 | None |
| Skin biopsy | 603 | More than 97% of doctors who do this |
Who their Medicare patients are
304 Original Medicare patients in 2024. Average age 74 · Women 59% · Also on Medicaid 6% · Health risk score 0.89. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 60% · Coronary heart disease 20% · Diabetes 16% · Depression 16% · Cancer 15% · Chronic kidney disease 13% · Atrial fibrillation 12% · COPD 7% · Stroke 7% · Heart failure 6% · Dementia 4%.
The office billed $601,170, Medicare allowed $268,173 and paid $204,018; for 5,156 services of 73 kinds; $2,729 of it was for drugs given in the office and $201,289 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 304 | 5,156 | 74 | 0.89 | $601,170 | $204,018 |
| 2023 | 296 | 6,520 | 74 | 0.92 | $639,190 | $215,368 |
| 2022 | 229 | 5,486 | 74 | 0.87 | $489,237 | $165,224 |
| 2021 | 191 | 3,834 | 73 | 0.81 | $389,829 | $126,806 |
| 2020 | 170 | 1,673 | 73 | 0.80 | $389,301 | $117,932 |
| 2019 | 193 | 1,722 | 72 | 0.81 | $425,451 | $151,771 |
| 2018 | 169 | 1,804 | 73 | 1.00 | $451,333 | $152,826 |
| 2017 | 181 | 2,240 | 73 | 0.98 | $489,088 | $164,033 |
| 2016 | 175 | 1,405 | 72 | 0.95 | $295,702 | $98,792 |
| 2015 | 140 | 1,248 | 71 | 0.81 | $257,440 | $79,756 |
| 2014 | 80 | 579 | 72 | 0.81 | $121,256 | $39,770 |
| 2013 | 21 | 74 | 74 | 0.81 | $27,809 | $6,971 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 21 services
| Short return visit (20+ min) | 185 | $33,384 | $72 |
| Return visit (30+ min) | 160 | $28,544 | $101 |
| Destruction of skin growth, 1-14 growths | 132 | $17,124 | $92 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 19 | $15,119 | $488 |
| Biopsy of related skin growth, first growth | 137 | $13,368 | $70 |
| Destruction of precancer skin growth, 1 growth | 166 | $11,233 | $38 |
| Biopsy of related skin growth, each additional growth | 82 | $9,630 | $46 |
| Punch biopsy, first skin growth | 55 | $7,049 | $108 |
| New patient visit (30+ min) | 68 | $6,069 | $89 |
| Destruction of precancer skin growth, 2-14 growths | 126 | $5,623 | $6 |
| Application of light with debridement to destroy precancer skin growth | 14 | $4,178 | $261 |
| Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | 14 | $4,155 | None |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 20 | $3,975 | $120 |
| New patient visit (45+ min) | 20 | $2,840 | $142 |
| Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | 15 | $2,478 | $85 |
| Administration of chemotherapy into growth, 1-7 | 17 | $2,308 | $55 |
| Short return visit | 34 | $1,883 | $47 |
| Punch biopsy, each additional skin growth | 12 | $1,073 | $54 |
| Injection into skin growth, 1-7 growths | 18 | $844 | $34 |
| Injection, fluorouracil, 500 mg | 18 | $182 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 18 | $50 | None |
2022: 20 services
| Short return visit (20+ min) | 156 | $27,989 | $71 |
| Return visit (30+ min) | 114 | $20,498 | $101 |
| Destruction of skin growth, 1-14 growths | 108 | $13,529 | $89 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 17 | $10,589 | $481 |
| Punch biopsy, first skin growth | 74 | $9,004 | $108 |
| Destruction of precancer skin growth, 1 growth | 131 | $8,918 | $39 |
| Biopsy of related skin growth, first growth | 89 | $8,832 | $72 |
| New patient visit (30+ min) | 79 | $7,198 | $91 |
| Biopsy of related skin growth, each additional growth | 66 | $6,199 | $47 |
| Destruction of precancer skin growth, 2-14 growths | 104 | $4,541 | $6 |
| Application of light with debridement to destroy precancer skin growth | 12 | $3,659 | $261 |
| Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | 12 | $3,538 | None |
| Administration of chemotherapy into growth, 1-7 | 20 | $3,322 | $62 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 11 | $2,192 | $146 |
| Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | 13 | $1,955 | $122 |
| Punch biopsy, each additional skin growth | 19 | $1,208 | $55 |
| Injection into skin growth, 1-7 growths | 12 | $799 | $36 |
| Short return visit | 14 | $752 | $50 |
| Injection, fluorouracil, 500 mg | 22 | $287 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $54 | None |
2021: 14 services
| Short return visit (20+ min) | 158 | $28,959 | $75 |
| Return visit (30+ min) | 82 | $12,483 | $104 |
| Destruction of skin growth, 1-14 growths | 97 | $11,766 | $96 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 11 | $7,129 | $509 |
| Punch biopsy, first skin growth | 51 | $6,529 | $111 |
| Biopsy of related skin growth, first growth | 64 | $6,361 | $77 |
| Destruction of precancer skin growth, 1 growth | 97 | $5,548 | $39 |
| Biopsy of related skin growth, each additional growth | 46 | $5,540 | $49 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 14 | $3,034 | $160 |
| New patient visit (30+ min) | 34 | $2,879 | $85 |
| Destruction of precancer skin growth, 2-14 growths | 71 | $2,333 | $6 |
| Punch biopsy, each additional skin growth | 17 | $1,244 | $57 |
| Injection into skin growth, 1-7 growths | 11 | $1,086 | $42 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $55 | None |
2020: 13 services
| Return visit (30+ min) | 148 | $28,811 | $88 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 13 | $8,593 | $452 |
| Biopsy of related skin growth, first growth | 68 | $7,436 | $77 |
| Biopsy of related skin growth, each additional growth | 57 | $7,086 | $48 |
| Destruction of skin growth, 1-14 growths | 60 | $6,463 | $86 |
| Punch biopsy, first skin growth | 44 | $5,529 | $108 |
| Destruction of precancer skin growth, 1 growth | 83 | $5,002 | $39 |
| Short return visit (20+ min) | 53 | $4,886 | $66 |
| New patient visit (30+ min) | 21 | $2,012 | $96 |
| Destruction of precancer skin growth, 2-14 growths | 61 | $1,609 | $6 |
| Punch biopsy, each additional skin growth | 12 | $1,119 | $56 |
| Injection into skin growth, 1-7 growths | 15 | $548 | $32 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 14 | $30 | None |
2019: 14 services
| Return visit (30+ min) | 167 | $35,943 | $89 |
| Biopsy of related skin growth, first growth | 117 | $12,255 | $76 |
| Biopsy of related skin growth, each additional growth | 79 | $11,457 | $48 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 17 | $9,828 | $517 |
| Destruction of skin growth, 1-14 growths | 79 | $9,775 | $91 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 12 | $8,535 | $356 |
| Destruction of precancer skin growth, 15 or more growths | 37 | $6,785 | $136 |
| Complicated repair of wound of trunk, 2.6-7.5 cm | 13 | $4,665 | $333 |
| Destruction of precancer skin growth, 1 growth | 84 | $4,560 | $38 |
| Short return visit (20+ min) | 49 | $4,205 | $60 |
| Punch biopsy, first skin growth | 33 | $3,944 | $107 |
| New patient visit (45+ min) | 28 | $3,696 | $132 |
| Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | 13 | $1,863 | $133 |
| Destruction of precancer skin growth, 2-14 growths | 46 | $997 | $5 |
2018: 16 services
| Return visit (30+ min) | 136 | $26,524 | $85 |
| Biopsy of single growth of skin and/or tissue | 122 | $14,881 | $71 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 18 | $12,373 | $458 |
| Destruction of skin growth, 1-14 growths | 81 | $10,486 | $95 |
| Biopsy of each additional growth of skin and/or tissue | 84 | $8,840 | $28 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 12 | $7,877 | $342 |
| Complicated repair of wound of trunk, 2.6-7.5 cm | 12 | $5,082 | $318 |
| New patient visit (45+ min) | 42 | $4,740 | $113 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 12 | $4,348 | None |
| Destruction of precancer skin growth, 1 growth | 74 | $3,955 | $36 |
| Destruction of precancer skin growth, 15 or more growths | 22 | $3,817 | $127 |
| Short return visit (20+ min) | 40 | $3,162 | $61 |
| Application of light by qualified health care professional to destroy precancer skin growth | 12 | $2,291 | $176 |
| Destruction of precancer skin growth, 2-14 growths | 52 | $1,160 | $5 |
| Injection into skin growth, 1-7 growths | 18 | $806 | $34 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 19 | $36 | None |
2017: 14 services
| Return visit (30+ min) | 142 | $26,980 | $86 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 24 | $15,304 | $494 |
| Biopsy of single growth of skin and/or tissue | 127 | $14,398 | $72 |
| Destruction of skin growth, 1-14 growths | 83 | $11,327 | $98 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 18 | $10,241 | $341 |
| Biopsy of each additional growth of skin and/or tissue | 86 | $7,566 | $28 |
| Destruction of precancer skin growth, 1 growth | 98 | $5,413 | $37 |
| Short return visit (20+ min) | 43 | $3,984 | $63 |
| New patient visit (45+ min) | 29 | $3,856 | $133 |
| Destruction of precancer skin growth, 15 or more growths | 22 | $3,597 | $128 |
| New patient visit (30+ min) | 43 | $3,281 | $76 |
| Destruction of precancer skin growth, 2-14 growths | 78 | $3,068 | $5 |
| Injection into skin growth, 1-7 growths | 16 | $682 | $31 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 18 | $36 | None |
2016: 13 services
| Return visit (30+ min) | 114 | $19,431 | $87 |
| Biopsy of single growth of skin and/or tissue | 104 | $10,995 | $76 |
| Destruction of skin growth, 1-14 growths | 64 | $9,049 | $97 |
| New patient visit (30+ min) | 64 | $5,129 | $80 |
| Destruction of precancer skin growth, 1 growth | 81 | $4,677 | $38 |
| Complicated repair of wound of trunk, 2.6-7.5 cm | 13 | $4,012 | $287 |
| Biopsy of each additional growth of skin and/or tissue | 67 | $3,410 | $27 |
| Long return visit (40+ min) | 22 | $2,767 | $111 |
| New patient visit (45+ min) | 20 | $2,705 | $135 |
| Short return visit (20+ min) | 32 | $2,034 | $58 |
| Destruction of precancer skin growth, 2-14 growths | 72 | $1,764 | $5 |
| Injection into skin growth, 1-7 growths | 13 | $502 | $36 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 13 | $20 | None |
2015: 9 services
| Return visit (30+ min) | 97 | $19,267 | $91 |
| Biopsy of single growth of skin and/or tissue | 79 | $7,701 | $75 |
| Destruction of skin growth, 1-14 growths | 50 | $7,184 | $95 |
| New patient visit (30+ min) | 82 | $7,045 | $86 |
| Destruction of precancer skin growth, 1 growth | 66 | $3,942 | $40 |
| Biopsy of each additional growth of skin and/or tissue | 48 | $2,555 | $26 |
| Pathology examination of tissue using a microscope, intermediate complexity | 37 | $2,470 | $33 |
| Destruction of precancer skin growth, 2-14 growths | 55 | $1,623 | $5 |
| Short return visit (20+ min) | 17 | $1,287 | $64 |
2014: 7 services
| Return visit (30+ min) | 49 | $9,201 | $93 |
| New patient visit (30+ min) | 58 | $5,163 | $89 |
| Biopsy of single growth of skin and/or tissue | 36 | $3,231 | $79 |
| Destruction of skin growth, 1-14 growths | 27 | $2,853 | $86 |
| Destruction of precancer skin growth, 1 growth | 38 | $2,408 | $48 |
| Destruction of precancer skin growth, 2-14 growths | 34 | $1,608 | $9 |
| Biopsy of each additional growth of skin and/or tissue | 19 | $802 | $26 |
2013: 1 service
| Return visit (30+ min) | 13 | $1,304 | $87 |
Medicaid work
$515 in 2024
Medicaid paid $515 for 2,846 billed services this clinician did in 2024, up to 189 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 1,798 | $205 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 66 | $151 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 384 | $89 |
| Short return visit (20+ min) | 110 | $52 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 13 | $19 |
| Injection, intralesional; up to and including 7 lesions | 57 | $0 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 205 | $0 |
| URINE PREGNANCY TEST | 201 | $0 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 12 | $0 |
| 2024 | 2,846 | 9 | 189 | $515 |
| 2023 | 3,225 | 9 | 199 | $115,516 |
| 2022 | 2,501 | 8 | 146 | $178,258 |
| 2021 | 1,865 | 7 | 68 | $127,700 |
| 2020 | 965 | 7 | 74 | $64,777 |
| 2019 | 2,752 | 11 | 82 | $130,009 |
| 2018 | 3,725 | 11 | 108 | $171,057 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 1,978 | $54,622 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 647 | $41,391 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 261 | $15,506 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 57 | $2,537 |
| Injection, intralesional; up to and including 7 lesions | 71 | $862 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 18 | $236 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 73 | $210 |
| URINE PREGNANCY TEST | 84 | $153 |
| Short return visit (20+ min) | 36 | $0 |
2022
| Return visit (30+ min) | 1,273 | $70,891 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 469 | $57,160 |
| Long return visit (40+ min) | 360 | $30,904 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 95 | $12,432 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 36 | $3,264 |
| Injection, intralesional; up to and including 7 lesions | 86 | $2,510 |
| URINE PREGNANCY TEST | 170 | $661 |
| Short return visit (20+ min) | 12 | $434 |
2021
| Long return visit (40+ min) | 634 | $54,285 |
| Return visit (30+ min) | 591 | $33,355 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 142 | $17,582 |
| OFFICE/OP CONSLTJ NEW/EST PT HIGH MDM 55 MINUTES | 89 | $13,750 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 41 | $5,308 |
| Injection, intralesional; up to and including 7 lesions | 79 | $2,288 |
| URINE PREGNANCY TEST | 289 | $1,133 |
2020
| Return visit (30+ min) | 541 | $30,210 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 104 | $12,858 |
| OFFICE/OP CONSLTJ NEW/EST PT HIGH MDM 55 MINUTES | 64 | $9,912 |
| Long return visit (40+ min) | 103 | $8,897 |
| Injection, intralesional; up to and including 7 lesions | 60 | $1,604 |
| Short return visit (20+ min) | 29 | $1,045 |
| URINE PREGNANCY TEST | 64 | $251 |
2019
| Return visit (30+ min) | 843 | $44,293 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 314 | $38,144 |
| ACNE SURGERY | 342 | $14,255 |
| Chemical exfoliation for acne (eg, acne paste, acid) | 324 | $10,855 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 55 | $7,563 |
| CRYOTHERAPY CO2 SLUSH LIQUID N2 ACNE | 342 | $6,907 |
| Injection, intralesional; more than 7 lesions | 250 | $3,719 |
| Short return visit (20+ min) | 74 | $2,285 |
| Injection, intralesional; up to and including 7 lesions | 66 | $1,144 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 127 | $787 |
| URINE PREGNANCY TEST | 15 | $57 |
2018
| OFF/OP CNSLTJ NEW/EST MOD 40 | 560 | $51,838 |
| Return visit (30+ min) | 1,066 | $45,361 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 236 | $24,775 |
| ACNE SURGERY | 427 | $21,414 |
| Chemical exfoliation for acne (eg, acne paste, acid) | 381 | $10,767 |
| CRYOTHERAPY CO2 SLUSH LIQUID N2 ACNE | 422 | $8,648 |
| Injection, intralesional; more than 7 lesions | 310 | $5,655 |
| Injection, intralesional; up to and including 7 lesions | 63 | $1,030 |
| Short return visit (20+ min) | 27 | $833 |
| URINE PREGNANCY TEST | 216 | $632 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 17 | $106 |
Drugs they prescribed that Part D paid
$2,068,994
Pharmacies billed $2,068,994 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 445) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
322 generic and 123 brand-name prescriptions · $2,068,994 in drug cost · 31 antibiotic prescriptions to 21 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vyjuvek | 86 | $2,007,559 | $23,344 |
| Opzelura | 13 | $25,577 | $1,967 |
| Ketoconazole | 68 | $1,008 | $15 |
| Fluorouracil | 15 | $818 | $55 |
| Tacrolimus | 11 | $808 | $73 |
See all 10 drugs
| Vyjuvek | 86 | $2,007,559 | $23,344 |
| Opzelura | 13 | $25,577 | $1,967 |
| Ketoconazole | 68 | $1,008 | $15 |
| Fluorouracil | 15 | $818 | $55 |
| Tacrolimus | 11 | $808 | $73 |
| Fluocinonide | 19 | $612 | $32 |
| Triamcinolone Acetonide | 53 | $453 | $9 |
| Minoxidil | 34 | $323 | $10 |
| Cephalexin | 17 | $142 | $8 |
| Finasteride | 23 | $69 | $3 |
Year by year
| 2024 | 445 | 133 | 0% (0) | 28% | $2,068,994 |
| 2023 | 334 | 128 | 0% (0) | 19% | $865,914 |
| 2022 | 316 | 125 | None | 3% | $61,838 |
| 2021 | 276 | 118 | None | 7% | $107,388 |
| 2020 | 276 | 108 | None | 8% | $57,995 |
| 2019 | 237 | 101 | None | 8% | $48,447 |
| 2018 | 196 | 78 | None | 15% | $24,118 |
| 2017 | 154 | 89 | None | 12% | $30,249 |
| 2016 | 148 | 72 | None | 22% | $102,333 |
| 2015 | 242 | 93 | None | 9% | $20,027 |
| 2014 | 204 | 95 | 8% (16) | 15% | $8,918 |
| 2013 | 158 | 76 | None | 28% | $15,473 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Vyjuvek | 32 | $811,501 | $25,359 |
| Ketoconazole | 58 | $1,369 | $24 |
| Tretinoin | 16 | $1,341 | $84 |
| Clobetasol Propionate | 25 | $1,202 | $48 |
| Fluorouracil | 16 | $1,171 | $73 |
| Triamcinolone Acetonide | 47 | $625 | $13 |
| Finasteride | 14 | $106 | $8 |
| Cephalexin | 13 | $40 | $3 |
2022: 7 drugs
| Ketoconazole | 66 | $2,028 | $31 |
| Fluorouracil | 21 | $2,004 | $95 |
| Clobetasol Propionate | 13 | $1,330 | $102 |
| Triamcinolone Acetonide | 48 | $996 | $21 |
| Imiquimod | 14 | $857 | $61 |
| Cephalexin | 32 | $210 | $7 |
| Finasteride | 18 | $175 | $10 |
2021: 5 drugs
| Ketoconazole | 53 | $1,651 | $31 |
| Fluocinonide | 23 | $1,109 | $48 |
| Fluorouracil | 14 | $1,105 | $79 |
| Triamcinolone Acetonide | 39 | $474 | $12 |
| Cephalexin | 29 | $236 | $8 |
2020: 7 drugs
| Ketoconazole | 46 | $1,639 | $36 |
| Doxycycline Hyclate | 13 | $1,068 | $82 |
| Fluocinonide | 18 | $997 | $55 |
| Triamcinolone Acetonide | 43 | $696 | $16 |
| Clindamycin Phosphate | 13 | $342 | $26 |
| Hydrocortisone | 13 | $249 | $19 |
| Cephalexin | 35 | $122 | $3 |
2019: 5 drugs
| Ketoconazole | 42 | $1,681 | $40 |
| Clindamycin Phosphate | 11 | $288 | $26 |
| Triamcinolone Acetonide | 25 | $263 | $11 |
| Hydrocortisone | 14 | $246 | $18 |
| Cephalexin | 46 | $199 | $4 |
2018: 4 drugs
| Ketoconazole | 32 | $3,527 | $110 |
| Triamcinolone Acetonide | 20 | $353 | $18 |
| Hydrocortisone | 15 | $234 | $16 |
| Cephalexin | 33 | $112 | $3 |
2017: 2 drugs
| Triamcinolone Acetonide | 15 | $201 | $13 |
| Cephalexin | 38 | $179 | $5 |
2016: 3 drugs
| Fluocinonide | 18 | $1,009 | $56 |
| Triamcinolone Acetonide | 14 | $309 | $22 |
| Cephalexin | 34 | $159 | $5 |
2015: 5 drugs
| Clobetasol Propionate | 18 | $3,607 | $200 |
| Fluocinonide | 18 | $1,353 | $75 |
| Cephalexin | 66 | $252 | $4 |
| Triamcinolone Acetonide | 17 | $179 | $11 |
| Ciprofloxacin | 21 | $139 | $7 |
2014: 6 drugs
| Fluocinonide | 21 | $1,320 | $63 |
| Clobetasol Propionate | 15 | $1,186 | $79 |
| Cephalexin | 56 | $284 | $5 |
| Hydrocodone-Acetaminophen | 15 | $248 | $17 |
| Triamcinolone Acetonide | 16 | $228 | $14 |
| Ketoconazole | 11 | $140 | $13 |
2013: 3 drugs
| Fluorouracil | 12 | $2,202 | $184 |
| Fluocinonide | 38 | $1,880 | $49 |
| Cephalexin | 14 | $70 | $5 |
Money from drug and device companies
$6,203 in 2025
| 2025 | 14 | 65 | $3,500 | $6,203 |
| 2024 | 14 | 26 | $3,500 | $4,518 |
| 2023 | 17 | 63 | $22,675 | $26,481 |
| 2022 | 17 | 53 | None | $1,107 |
| 2021 | 12 | 37 | None | $869 |
| 2020 | 10 | 17 | None | $399 |
| 2019 | 19 | 47 | None | $1,018 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Krystal Biotech | Vyjuvek | $4,610 | 11 payments
|
| Incyte | Opzelura | $368 | 16 payments
|
| Pfizer | Cibinqo | $272 | 10 payments
|
| Solta Medical a division of Bausch Health US | None | $234 | 3 payments
|
| Chiesi USA | Filsuvez | $225 | 5 payments
|
| Genzyme | Dupixent | $144 | 5 payments
|
See all 65 published payments
| Krystal Biotech | Paid to speak or teach · 2025-12-18 | Vyjuvek | $3,500 |
| Chiesi USA | Meals · 2025-12-16 | Filsuvez | $30 |
| Pfizer | Meals · 2025-12-12 | Cibinqo | $17 |
| Krystal Biotech | Meals · 2025-12-11 | Vyjuvek | $125 |
| Krystal Biotech | Travel · 2025-12-11 | Vyjuvek | $867 |
| LEO Pharma | Meals · 2025-12-02 | Adbry | $17 |
| Incyte | Meals · 2025-11-24 | Opzelura | $24 |
| Pfizer | Meals · 2025-11-18 | Cibinqo | $21 |
| Krystal Biotech | Meals · 2025-11-13 | Vyjuvek | $8 |
| Regeneron Healthcare Solutions | Meals · 2025-11-05 | Libtayo | $27 |
| Incyte | Meals · 2025-11-03 | Opzelura | $19 |
| Novartis Pharmaceuticals | Meals · 2025-10-31 | Rhapsido | $19 |
| Krystal Biotech | Meals · 2025-10-29 | Vyjuvek | $22 |
| Krystal Biotech | Meals · 2025-10-29 | Vyjuvek | $1 |
| Abbvie | Meals · 2025-10-29 | Botox | $22 |
| Pfizer | Meals · 2025-10-28 | Cibinqo | $23 |
| Genzyme | Meals · 2025-10-27 | Dupixent | $17 |
| Pfizer | Meals · 2025-10-25 | Litfulo | $58 |
| Incyte | Meals · 2025-10-24 | Opzelura | $65 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-10-23 | None | $31 |
| Pfizer | Meals · 2025-10-23 | Cibinqo | $62 |
| Chiesi USA | Meals · 2025-10-17 | Filsuvez | $31 |
| LEO Pharma | Meals · 2025-10-13 | Adbry | $24 |
| Regeneron Healthcare Solutions | Meals · 2025-10-07 | Dupixent | $38 |
| Incyte | Meals · 2025-10-07 | Opzelura | $18 |
| Abbvie | Meals · 2025-09-26 | Rinvoq | $18 |
| Incyte | Meals · 2025-09-23 | Opzelura | $7 |
| Janssen Biotech | Meals · 2025-09-11 | Tremfya | $29 |
| Incyte | Meals · 2025-09-08 | Opzelura | $11 |
| Incyte | Meals · 2025-09-04 | Opzelura | $112 |
| Arcutis Biotherapeutics | Meals · 2025-08-29 | Zoryve | $21 |
| Abbvie | Meals · 2025-08-27 | Rinvoq | $21 |
| Incyte | Meals · 2025-08-21 | Opzelura | $27 |
| Solta Medical a division of Bausch Health US | Meals · 2025-08-11 | None | $47 |
| Genzyme | Meals · 2025-07-16 | Dupixent | $41 |
| Incyte | Meals · 2025-07-11 | Opzelura | $7 |
| Incyte | Meals · 2025-07-11 | Opzelura | $13 |
| Chiesi USA | Meals · 2025-07-09 | Filsuvez | $31 |
| Chiesi USA | Education · 2025-07-09 | Filsuvez | $39 |
| Novartis Pharmaceuticals | Meals · 2025-07-02 | Cosentyx | $20 |
| Incyte | Meals · 2025-06-30 | Opzelura | $6 |
| Incyte | Meals · 2025-06-30 | Opzelura | $8 |
| Krystal Biotech | Meals · 2025-06-25 | Vyjuvek | $22 |
| Krystal Biotech | Meals · 2025-06-20 | Vyjuvek | $19 |
| Pfizer | Meals · 2025-06-18 | Cibinqo | $23 |
| Amgen | Meals · 2025-06-10 | Otezla | $16 |
| Incyte | Meals · 2025-06-09 | Opzelura | $7 |
| Incyte | Meals · 2025-06-09 | Opzelura | $5 |
| Krystal Biotech | Meals · 2025-06-04 | Vyjuvek | $12 |
| Krystal Biotech | Meals · 2025-05-16 | Vyjuvek | $17 |
| Abbvie | Meals · 2025-05-16 | Rinvoq | $18 |
| Pfizer | Meals · 2025-05-06 | Cibinqo | $20 |
| Incyte | Meals · 2025-04-28 | Opzelura | $23 |
| Genzyme | Meals · 2025-04-08 | Dupixent | $38 |
| Genzyme | Meals · 2025-03-31 | Dupixent | $11 |
| Abbvie | Meals · 2025-03-12 | Rinvoq | $30 |
| Genzyme | Meals · 2025-02-11 | Dupixent | $38 |
| Chiesi USA | Meals · 2025-02-11 | Filsuvez | $94 |
| Pfizer | Meals · 2025-02-04 | Cibinqo | $29 |
| Incyte | Meals · 2025-01-24 | Opzelura | $19 |
| Pfizer | Meals · 2025-01-23 | Cibinqo | $2 |
| Krystal Biotech | Meals · 2025-01-14 | Vyjuvek | $16 |
| Pfizer | Meals · 2025-01-08 | Cibinqo | $18 |
| Solta Medical a division of Bausch Health US | Meals · 2025-01-03 | None | $61 |
| Solta Medical a division of Bausch Health US | Meals · 2025-01-03 | None | $127 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $4,518
| Krystal Biotech | Vyjuvek | $3,661 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | None | $432 | 2 payments
|
| Abbvie | Rinvoq | $74 | 4 payments
|
| Novartis Pharmaceuticals | Cosentyx | $67 | 2 payments
|
| Arcutis Biotherapeutics | Zoryve | $52 | 4 payments
|
| Genzyme | Dupixent | $42 | 1 payment
|
| Verrica Pharmaceuticals | Ycanth | $35 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $34 | 1 payment
|
| LEO Pharma | Adbry | $32 | 1 payment
|
| Janssen Biotech | Tremfya | $30 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $20 | 1 payment
|
| Incyte | Opzelura | $18 | 1 payment
|
| Amgen | Otezla | $17 | 1 payment
|
| Pfizer | Eucrisa | $4 | 1 payment
|
2023: $26,481
| Krystal Biotech | Vyjuvek | $22,391 | 15 payments
|
| Novartis Pharmaceuticals | Vijoice | $2,879 | 9 payments
|
| Boehringer Ingelheim Pharmaceuticals | None | $218 | 8 payments
|
| Avita Medical Americas | Recell | $175 | 1 payment
|
| Incyte | Opzelura | $142 | 4 payments
|
| Abbvie | Rinvoq | $131 | 5 payments
|
| Galderma Laboratories L.P. | None | $130 | 1 payment
|
| Pfizer | Eucrisa | $105 | 10 payments
|
| Genzyme | Dupixent | $71 | 2 payments
|
| Ucb | Bimzelx | $46 | 1 payment
|
| Ortho Dermatologics a division of Bausch Health US | Targretin | $42 | 1 payment
|
| Janssen Biotech | Remicade | $33 | 1 payment
|
| LEO Pharma | Adbry | $31 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $30 | 1 payment
|
| Almirall | Seysara | $25 | 1 payment
|
| Blueprint Medicines | None | $17 | 1 payment
|
| Lilly USA | Taltz | $15 | 1 payment
|
2022: $1,107
| Genzyme | Libtayo | $307 | 8 payments
|
| Abbvie | Rinvoq | $150 | 6 payments
|
| Pfizer | Eucrisa | $105 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | None | $95 | 1 payment
|
| LEO Pharma | Adbry | $87 | 3 payments
|
| Novartis Pharmaceuticals | Cosentyx | $73 | 4 payments
|
| Incyte | Opzelura | $47 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $42 | 2 payments
|
| EPI Health | Cloderm | $41 | 2 payments
|
| Janssen Biotech | Remicade | $25 | 1 payment
|
| Sun Pharmaceutical Industries | Winlevi | $24 | 1 payment
|
| Blueprint Medicines | None | $23 | 1 payment
|
| Janssen Scientific Affairs | Tremfya | $22 | 1 payment
|
| Mayne Pharma | None | $22 | 1 payment
|
| Lilly USA | Taltz | $20 | 1 payment
|
| Galderma Laboratories L.P. | Epsolay | $13 | 1 payment
|
| Amgen | Otezla | $12 | 1 payment
|
2021: $869
| Pfizer | Eucrisa | $245 | 15 payments
|
| Novartis Pharmaceuticals | Cosentyx | $159 | 6 payments
|
| Merz North America | None | $144 | 1 payment
|
| Sanofi-Aventis U.S. | Dupixent | $83 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $58 | 2 payments
|
| Sun Pharmaceutical Industries | Absorica Ld | $52 | 3 payments
|
| Amgen | Otezla | $32 | 1 payment
|
| Dermira | Qbrexza | $24 | 1 payment
|
| Lilly USA | Taltz | $22 | 1 payment
|
| Incyte | Opzelura | $18 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $17 | 1 payment
|
| Galderma Laboratories L.P. | None | $16 | 1 payment
|
2020: $399
| Regeneron Healthcare Solutions | Dupixent | $145 | 4 payments
|
| Pfizer | Eucrisa | $61 | 3 payments
|
| AbbVie | Skyrizi | $39 | 2 payments
|
| Amgen | Otezla | $39 | 2 payments
|
| Sun Pharmaceutical Industries | Absorica Ld | $29 | 1 payment
|
| Allergan | Botox Cosmetic | $21 | 1 payment
|
| Novartis Pharmaceuticals | Cosentyx | $20 | 1 payment
|
| Ortho Dermatologics a division of Bausch Health US | Duobrii | $18 | 1 payment
|
| Sanofi-Aventis U.S. | Dupixent | $15 | 1 payment
|
| Lilly USA | Taltz | $14 | 1 payment
|
2019: $1,018
| Novartis Pharmaceuticals | Cosentyx | $228 | 8 payments
|
| Pfizer | Eucrisa | $148 | 5 payments
|
| Genzyme | Dupixent | $71 | 3 payments
|
| Regeneron Healthcare Solutions | Dupixent | $71 | 3 payments
|
| Lilly USA | Taltz | $62 | 4 payments
|
| Galderma Laboratories L.P. | Soolantra | $61 | 3 payments
|
| Biofrontera | Ameluz | $58 | 3 payments
|
| Sun Pharmaceutical Industries | Absorica | $56 | 3 payments
|
| Ortho Dermatologics a division of Bausch Health US | Bryhali | $47 | 3 payments
|
| EPI Health | Sitavig | $33 | 1 payment
|
| DUSA Pharmaceuticals | Blu-U | $33 | 2 payments
|
| AbbVie | Humira | $32 | 2 payments
|
| Sanofi-Aventis U.S. | No Product Discussed | $21 | 1 payment
|
| LEO Pharma | Enstilar | $20 | 1 payment
|
| Helsinn Therapeutics (U.S.) | Valchlor | $17 | 1 payment
|
| Celgene | None | $17 | 1 payment
|
| Sensus Healthcare | None | $16 | 1 payment
|
| Allergan | Botox Cosmetic | $15 | 1 payment
|
| Merz North America | Xeomin | $12 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Krystal Biotech Inc · Open Label Treatment of Beremagene Geperpavec (B-Vec) · 2023 | Their institution | $239,509 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Safety & Efficacy of Speso in Pts With Netherton Syndrome · 2024 | Their institution | $64,383 |
| SANOFI US SERVICES INC. · A Multicenter Open-Label Study To Investigate the Pharmacokinetics and Safety of Dupilumab in Participants >=6 Months To <18 Years of Age With Prurigo Nodularis · 2025 | Their institution | $37,125 |
| PFIZER INC. · A Phase 3 Randomized Doubleblind 52week Placebocontrolled Multicenter Study With A Doubleblind 52week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo · 2025 | Their institution | $36,417 |
| Krystal Biotech Inc · Phase 1 Open-Label Multicenter Dose Escalation and Expansion Study To Evaluate the Safety and Tolerability of Kb707 in Adults With Locally Advanced Or Metastatic Solid Tumors · 2024 | Their institution | $31,308 |
| Boehringer Ingelheim International GmbH · Non-Interventional Study of Patients With Netherton Syndrome To Characterise the Natural History of Disease · 2025 | Their institution | $16,752 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Safety & Efficacy of Speso in Pts With Netherton S · 2023 | Their institution | $16,179 |
| Arcutis Biotherapeutics, Inc. · A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of Arq-151 Cream 0.05% Administered Qd in Subjects With Atopic Dermatitis · 2023 | This clinician | $14,397 |
| Arcutis Biotherapeutics, Inc. · A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of Arq-151 Cream 0.15% and Arq-151 Cream 0.05% in Subjects With Atopic Dermatitis · 2023 | This clinician | $14,355 |
| SANOFI US SERVICES INC. · A Multicenter Open-Label Study To Investigate the Pharmacokinetics and Safety of Dupilumab in Participants >=6 Months To <18 Years of Age With Prurigo Nodularis · 2024 | Their institution | $14,021 |
| Organon Llc · Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects · 2025 | Their institution | $13,009 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Evasayiltm : A Placebo-Controlled Trial To Evaluate the Efficacy and Safety of Spesolimab in the Treatment of Patients With Netherton Syndrome · 2025 | Their institution | $11,688 |
| SANOFI US SERVICES INC. · Registry To Characterize the Patients Who Receive Dupixent for Pn in A Real-World Setting · 2025 | Their institution | $11,147 |
| SANOFI US SERVICES INC. · Registry To Characterize the Patients Who Receive Dupixent for Pn in A Real-World Setting · 2024 | Their institution | $10,479 |
| Arcutis Biotherapeutics, Inc. · A Phase 2, Open Label, 4-Week, Safety Study of Roflumilastcream 0.05% Administered Once Daily in Infants Aged 3months To Less Than 2 Years With Atopicdermatitis · 2025 | Their institution | $8,500 |
| Arcutis Biotherapeutics, Inc. · A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of Arq-151 Cream 0.15% and Arq-151 Cream 0.05% in Subjects With Atopic Dermatitis · 2024 | This clinician | $8,370 |
| PFIZER INC. · A Phase 3 Randomized Doubleblind 52week Placebocontrolled Multicenter Study With A Doubleblind 52week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo · 2024 | Their institution | $8,322 |
| Boehringer Ingelheim International GmbH · Safety & Efficacy of Speso in Pts With Netherton S · 2023 | Their institution | $5,389 |
| Arcutis Biotherapeutics, Inc. · A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of Arq-151 Cream 0.3% in Subjects With Chronic Plaque Psoriasis Who Have Completed Preceding Studies Arq-151-301 Or Arq-151-302 · 2024 | This clinician | $2,376 |
| Boehringer Ingelheim International GmbH · Safety & Efficacy of Speso in Pts With Netherton Syndrome · 2024 | Their institution | $2,355 |
| PFIZER INC. · A Phase 3 Randomized Doubleblind 52week Placebocontrolled Multicenter Study With A Doubleblind 52week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo · 2023 | Their institution | $1,452 |
| Arcutis Biotherapeutics, Inc. · A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of Arq-151 Cream 0.15% Administered Qd in Subjects With Atopic Dermatitis · 2023 | This clinician | $1,198 |
| Arcutis Biotherapeutics, Inc. · A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of Arq-151 Cream 0.3% in Subjects With Chronic Plaque Psoriasis Who Have Completed Preceding Studies Arq-151-301 Or Arq-151-302 · 2023 | This clinician | $500 |
| Boehringer Ingelheim International GmbH · Evasayiltm : A Placebo-Controlled Trial To Evaluate the Efficacy and Safety of Spesolimab in the Treatment of Patients With Netherton Syndrome · 2025 | Their institution | $263 |
| Arcutis Biotherapeutics, Inc. · A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of Arq-151 Cream 0.05% Administered Qd in Subjects With Atopic Dermatitis · 2024 | This clinician | $245 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 0.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1033287180
- Licence
- CA A95744California A95744: Current · expires 2028-02-29
- Trained
- Stanford University School of Medicine, 2002
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207NP0225X (207NP0225X); Federal specialty code 174400000X (174400000X); Federal specialty code 207N00000X (207N00000X); Federal specialty code 207ND0101X (207ND0101X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2006-11-30
- NPI last updated
- 2024-04-29
- NPI record certified
- 2024-04-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 30 Calle Aveituna, San Clemente, CA, 92673